Biosynthesis of tauro-ursodeoxycholic acid (TUDCA) in Saccharomyces cerevisiae.

Seonyun Moon, Michael J Smanski

Abstract read

In one paragraph

Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seonyun MoonDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Twin Cities, 55455, Minneapolis, USA.

Michael J SmanskiDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Twin Cities, 55455, Minneapolis, USA. smanski@umn.edu.

Funding

Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's DiseaseR42AG083665 · NIA · METSELEX, INC. · PI GEORG, GUNDA I., LOW, WALTER C · 2023 to 2025

$2.9M

Microbial Synthesis of Therapeutic Bile AcidsR41NS113732 · NINDS · METSELEX, INC. · PI LIAO, DEZHI, LOW, WALTER C · 2020 to 2020

$450k

National Institutes of Health, USA 9R42AG083665NIA NIH HHS R42 AG083665NINDS NIH HHS R41 NS113732

6 · The paper itself

Abstract

Tauroursodeoxycholic acid (TUDCA) is a microbial bile acid known for its diverse yet still largely unexplored biological activities. Traditionally used in Asian medicine, TUDCA and the taurine-free form, ursodeoxycholic acid (UDCA), share similar therapeutic properties. Recent studies suggest that TUDCA is a promising lead compound for developing neuroprotective agents to prevent neurodegenerative diseases such as Parkinson's disease and Huntington's disease. However, sustainable and ethical sources for large-scale TUDCA production remain unavailable. To address this, we are engineering a yeast-based microbial platform capable of producing TUDCA via fermentation. Here we report strains capable of converting the more widely available primary bile acid, chenodeoxycholic acid (CDCA) into TUDCA. This was achieved by introducing heterologous genes enabling taurine conjugation and taurine biosynthesis, providing a sustainable and scalable approach for TUDCA production.

Indexed as

Saccharomyces cerevisiaeTaurochenodeoxycholic AcidChenodeoxycholic AcidFermentationMetabolic EngineeringTaurineUrsodeoxycholic AcidChenodeoxycholic AcidTaurineTaurochenodeoxycholic AcidUrsodeoxycholic AcidursodoxicoltaurineGenetic design optimizationMetabolic pathway engineeringMicrobial bile acids

Identifiers

PMID41039607

DOI10.1186/s12934-025-02829-3

PMCPMC12492934

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.